News Releases

Month Year

Month Year

May 7, 2020

Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 7, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2020

Insmed Announces Pricing of Public Offering of Common Stock
May 4, 2020

Insmed Announces Proposed Public Offering of Common Stock
Apr 30, 2020

Insmed Reports First Quarter 2020 Financial Results and Provides Business Update

--Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--
Apr 23, 2020

Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial

--Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--
Apr 20, 2020

Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020
Apr 3, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 2, 2020

Insmed Appoints Carol A. Schafer to its Board of Directors
Mar 16, 2020

Insmed Provides Business Update

-- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation